One-Day Prostate Cancer Diagnosis: Biparametric Magnetic Resonance Imaging and Digital Pathology by Fluorescence Confocal Microscopy
Authors:
- Ugo Giovanni FalagarioUFUgo Giovanni Falagario
- Oscar SelvaggioOSOscar Selvaggio
- Francesca SanguedolceFSFrancesca Sanguedolce
- Paola MililloPMPaola Milillo
- Maria Chiara SighinolfiMSMaria Chiara Sighinolfi
- Salvatore Mariano BrunoSBSalvatore Mariano Bruno
- Marco RecchiaMRMarco Recchia
- Carlo BettocchiCarlo Bettocchi
- Gian Maria BusettoGian Maria Busetto
- Luca MacariniLMLuca Macarini
- Bernardo RoccoBRBernardo Rocco
- Luigi CormioLCLuigi Cormio
Open Access
- 21 January 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 277
Abstract
In this prospective observational study, we tested the feasibility and efficacy of a novel one-day PCa diagnosis path based on biparametric magnetic resonance (bpMRI) and digital pathology by fluorescence confocal microscopy (FCM). Patients aged 55–70 years scheduled for PBx due to increased PSA levels (3–10 ng/mL) and/or abnormal digitorectal examination were enrolled. All patients underwent bpMRI and PBx with immediate FCM evaluation of biopsy cores. Patients were asked to fill out a dedicated Patient Satisfaction Questionnaire. Patients’ satisfaction rates and concordance between digital pathology and standard HE evaluation were the outcomes of interest. Twelve patients completed our one-day PCa diagnosis path. BpMRI showed suspicious lesions in 7 patients. Digital pathology by FCM identified PCa in 5 (41.7%) of the 12 patients. Standard pathology confirmed the diagnosis made through digital pathology in all the cases. At a per patient level, high concordance between the methods was achieved in Gleason Grading (4 out of 5 patients). The level of agreement in the number of positive cores was lower but did not affect the choice of treatment in any of the 5 PCa cases. At a per core level, the agreement was very high for the diagnosis of anyPCa (96.2%) and csPCa (97.3%), with a k coefficient of 0.90 and 0.92, respectively (near perfect agreement). In conclusion, one-day PCa diagnosis by FCM represents a feasible, reliable, and fast diagnostic method that provides significant advantages in optimizing time and resources, leading to patients having a higher quality standard of care perception.Keywords
This publication has 30 references indexed in Scilit:
- A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous CohortsEuropean Urology, 2018
- Screening for Prostate CancerJAMA, 2018
- MRI-Targeted or Standard Biopsy for Prostate-Cancer DiagnosisNew England Journal of Medicine, 2018
- Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial)Journal of Magnetic Resonance Imaging, 2017
- The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer ScreeningUrology, 2016
- Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate BiopsyMedicine, 2016
- Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer.2015
- Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsyJournal of Magnetic Resonance Imaging, 2014
- Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?World Journal of Urology, 2012
- Combined perianal‐intrarectal (PI) lidocaine‐prilocaine (LP) cream and lidocaine‐ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsyBJU International, 2011